Bright Minds Biosciences Inc. DRUG
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 77.28% | -40.51% | -82.94% | 21.72% | -84.33% |
| Total Depreciation and Amortization | -2.08% | 1.41% | 15.45% | 6.96% | -26.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,129.29% | -108.01% | 67.40% | -23.14% | 240.13% |
| Change in Net Operating Assets | -179.26% | 243.68% | -182.61% | 415.42% | -183.95% |
| Cash from Operations | 10.60% | -61.57% | -353.16% | 63.65% | -49.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.38% | -1.15% | 0.38% | -1.95% | -4.07% |
| Issuance of Common Stock | -99.95% | 1,643.65% | -61.47% | 411,377.27% | -96.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -2,660.51% | 81.29% | -- | -- |
| Cash from Financing | -99.96% | 1,633.91% | -60.29% | 198,381.97% | -107.77% |
| Foreign Exchange rate Adjustments | 345.21% | 200.76% | -168.11% | 31.13% | -4,666.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.84% | 3,552.49% | -80.76% | 837.67% | -100.85% |